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ABSTRACT 
 
25-Hydroxyvitamin D, IGF-1, and Waist Circumference A Cross-Sectional Study 
 
by 
 
Damon McCune 
 
Dr. Laura Kruskall, Examination Committee Chair 
Associate Professor, Director of Nutrition Sciences  
University of Nevada, Las Vegas 
 
 
 
Purpose: Waist circumference has been shown to have a link to various forms of chronic 
disease and low levels of Vitamin D (25(OH)D) and IGF-1. The purpose of this study is 
to assess if there is a relationship with Vitamin D (25(OH)D) and IGF-1 levels and waist 
circumference. 
Methods: As part of a cross-sectional correlation study, participants were males and 
females (n=26), ages 25-65, who were students at UNLV and/or individuals who attend 
local health and wellness facilities as well as attendees of classes held by the UNLV 
Nutrition Center.  Participants reported to UNLV to review and sign informed consent 
and submit a finger stick blood draw under sterile conditions as well as resting blood 
pressure and waist circumference. The finger stick blood draw sample was used to 
obtain serum 25(OH)D and IGF-1 levels using ELISA kits. Participants completed food 
frequency questionnaires asking about eating habits prior to study and surveys were 
administered to determine level and type of physical activity. Participants then reported 
to a local Quest Diagnostics at their convenience to obtain a fasting comprehensive 
metabolic panel. Data were collected and evaluated using Microsoft Excel and SPSS 
software.  
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Results: Subjects were separated into two groups according to waist circumference 
(Female >35”, Male >40”) Data reflected no significant difference between large waist 
and normal waist circumference groups in regards to both IGF-1 and 25(OH)D. Data did 
reflect, however, that a significant relationship between IGF-1 and waist circumference 
did exist (P=.006). Although, a significant relationship between 25(OH)D and waist 
circumference did not exist. 
Conclusion: Waist circumference has an inverse relationship to IGF-1. Abdominal 
obesity may cause a reduction in the amount of free IGF-1 produced by the body which 
could increase risk for chronic disease. Obtaining waist circumference as well as 
activity level is relatively convenient in medical treatment settings and could 
provide clinicians with more valuable information regarding patient’s level of risk 
for disease. 
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CHAPTER 1 
 
INTRODUCTION 
Risk of Abdominal Obesity 
 
Waist circumference has been shown to be reflected to many aspects of 
adverse health conditions including cardiovascular disease (CVD), hypertension, 
hyperlipidemia, and diabetes mellitus. Since CVD is the leading cause of morbidity 
and mortality in many countries worldwide, the high correlation to waist 
circumference and risk of CVD needs to be further investigated. 1 
Conditions Associated with Abdominal Obesity-Metabolic Syndrome 
Waist circumference has also been linked to indicators of Metabolic 
Syndrome. Metabolic syndrome is the co-occurrence of the health conditions 
previously mentioned related to waist circumference. While this body of work will 
not be focusing on all indicators of Metabolic Syndrome, understanding the 
conditions associated with Metabolic Syndrome and how those relate to waist 
circumference is crucial. To assess Metabolic Syndrome, it is important to 
understand that it is not a condition defined by one disease condition but rather a 
cluster of several co-occurring cardiovascular risk factors that significantly increase 
an individual’s risk for a cardiovascular event. These factors include; insulin 
resistance, hypertension, atherogenic dyslipidemia, and obesity (mainly abdominal 
obesity).1 Although these factors all have individual parameters for diagnosis and 
individual health threats, when combined they pose increased risk for a 
cardiovascular event to occur even if they only carry a borderline diagnosis. All may 
be controlled through dietary and lifestyle changes. 
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 Insulin resistance is a condition in which the body produces insulin but does 
not utilize it properly. The biochemistry of this action can be described partially by 
the binding of insulin mainly to insulin receptors on cells and also through insulin 
like growth factor-1 (IGF-1) receptors. IGF-1, a polypeptide hormone, plays a role in 
proliferation and differentiation of cells and has apoptosis properties. These traits 
may be the reason it has a relationship to chronic diseases. Insulin sensitivity can be 
adversely altered due to obesity, in particular abdominal obesity.² Cellular actions of 
insulin depend on a wide variety of effects on post receptor signaling pathways 
within target cells.  The beta subunit of the insulin receptor is a tyrosine kinase, 
which is activated when insulin binds to the alpha subunit. The kinase 
autophophorylates and mediates multiple activities of insulin. Insulin receptor 
concentration or affinity may be altered due to obesity, physical inactivity, ambient 
insulin levels, various physiological and disease states, and drugs. The secretion of 
insulin and insulin sensitivity are reciprocally related which means that insulin 
resistance results in an increase in insulin secretion to maintain normal glucose and 
lipid homeostasis. There is also an inverse association between serum 25(OH)D and 
insulin resistance. Some researchers hypothesize that the insulin resistance is 
caused by low levels of circulating 25(OH)D, while other researchers believe that 
obesity, in particular central obesity, is the cause of both low levels of circulating 
25(OH)D and insulin resistance.²¯³  
 The final component of metabolic syndrome is obesity. Some believe this to 
be the cause and others find it as a byproduct to the other conditions associated. 
Regardless of the view of this condition, it plays a major role in the risk and systemic 
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pathophysiology of cardiovascular disease. It should be noted that having too much 
body fat is considered different from being overweight, or simply weighing too 
much. The most common measurement of obesity is the Body Mass Index (BMI), and 
is a measurement of height (in meters)/weight (in kilograms2). A normal range is 
between 18-25 m/kg2, overweight is considered between 25-29.9 m/kg2, obese is 
considered over 30 m/kg2, and underweight is below 18 m/kg2. Recent literature 
has introduced a modified approach to also include abdominal obesity to the 
measurement by including a waist circumference measurement. This method is 
referred to as the Body Shape Index (ABSI), and was introduced by Nir Krakauer, et 
al. The ABSI formula is WC/(BMI⅔Height1/2).1 
Population at Risk 
An accumulation of body fat, usually twenty percent or more over an 
individual’s ideal body weight is also considered to make an individual obese and 
increases risk for chronic disease. The accumulation of excess body fat in the 
abdominal area in particular also increases risk for cardiovascular events and 
chronic disease. The cause of this condition is simply consuming more energy than 
is expended by the body. While the cause of this condition is simple and easy to 
counteract, gaining compliance from patients seems to be one of the most difficult 
tasks facing medical professionals. 4 
Clinical Indicators of Metabolic Syndrome 
The National Cholesterol Education Program Adult Treatment Panel III (NCEP-
ATP III) criteria was used to define large waistline and high fasting glucose. The 
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NCEP-ATP III defines criteria of metabolic syndrome as any three of the following 
traits in the same individual: 3 
 Large Waistline – Men: 40 inches (102cm) or more, and women: 35 inches 
(88cm) or more. 
 High Triglycerides – 150 mg/dL or more 
 Low HDL Cholesterol – Men: 40 mg/dL or less, and women: 50 mg/dL or less 
 High Blood Pressure – 130/85 mmHg or more 
 High Fasting Glucose – 110 mg/dL or more 
It has been shown that individuals borderline on these indicators also show an 
increased risk for a cardiovascular event as well as those with extremely high 
values. Also, according to the American Heart Association estimated $475.3 billion 
cost for cardiovascular disease and stroke in the United States for 2009.5 
Impact on Organs 
Organs usually affected by metabolic syndrome include, but are not limited 
to; heart, brain, pancreas, kidneys, lungs, liver, and arteries. The main organ 
impacted by the condition would be the heart. Due to the increase in resistance of 
blood flow in arteries, cardiac output is decreased thus forcing the heart to work 
harder. This is compounded by the fluid retention that is common in those who are 
obese or suffer from kidney complications which further increases strain to the 
heart. To further add to this strain, liver complications can further increase 
dyslipidemia in patients which also compounds these previously mentioned 
complications to the heart. Finally, possibly at the forefront of the complications, 
pancreatic dysfunction or insulin resistance does not allow for the utilization of 
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glucose and lipids properly. Lack of glucose to supply the brain with usable fuel can 
lead to dysfunction systemically in the body including respiratory dysfunction and 
all of these systemic complications, when co-occurring, compound each other and 
further impose strain on the heart until it can no longer handle the load. 
 Individuals that meet criteria of metabolic syndrome are usually found to be 
over-nourished and have a large waist circumference. These individuals are 
generally not deficient in nutrients, although acute deficiency may occur depending 
on lifestyle or secondary conditions. Among these deficiencies, vitamin D deficiency 
seems to be one of the most prevalent conditions. These acute deficiencies are easily 
manageable when compared to combatting the over-intake of macronutrients and 
energy.4 
The purpose of this study is to explore the relationship between 25-
hydroxyvitamin D (25(OH0D), IGF-1, and waist circumference. 
Question 1: Is there a relationship that exists between 25(OH)D and waist 
circumference? 
Ho: Serum 25(OH)D levels have no association with waist circumference  
H1: Serum 25(OH)D levels will be inversely associated with waist 
circumference. 
Question 2: Is there a relationship that exists between IGF-1 and waist circumference? 
Ho: Serum free IGF-1 levels have no association with waist circumference. 
H1: Serum free IGF-1 levels will be inversely associated with waist 
circumference. 
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Question 3: Do individuals with large waist circumference have lower levels of serum 
IGF-1 than those with normal waist circumferences? 
Ho: Individuals with large waist circumference will not have a lower level of 
serum IGF-1 than those with normal waist circumference. 
H1: Individuals with large waist circumference will have a lower level of 
serum IGF-1 than those with normal waist circumference. 
Question 4: Do individuals with large waist circumference have lower levels of serum 
25(OH)D than those with normal waist circumference? 
Ho: Individuals with large waist circumference will not have a lower level of 
serum 25(OH)D than those with normal waist circumference. 
H1: Individuals with large waist circumference will have a lower level of 
serum 25(OH)D than those with normal waist circumference. 
Recently, several studies have supported dietary and lifestyle approaches for 
reducing risk factors related to cardiovascular disease (CVD) that provide 
information as to why maintaining a healthy waist circumference is vital. 
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CHAPTER 2 
 
REVIEW OF LITERATURE 
  
Body Shape Index Validity 
Recently, researchers have sought to produce a formula to include some form 
of body composition to the Body Mass Index (BMI) even in complex settings when 
conventional tools of measurement may not be accessible. This measurement could 
provide clinicians with a more accurate depiction of risk in patients since the BMI 
does not always reflect accurately on individuals whose weight is primarily skeletal 
muscle with little body fat. Nir Krakauer, et al, introduced the Body Shape Index 
(ABSI) to provide a useful and practical tool for those situations where patients are 
non-ambulatory conventional composition tools are not available. 1 
 The World Health Organization (WHO) rank weight and obesity fifth among 
causes of death worldwide. Validity of BMI-based obesity guidelines has come into 
question since BMI does not distinguish between muscle and fat mass and 
accumulation. Abdominal fat accumulation has been shown to increase risk of 
disease more so than accumulation of fat in other areas of the body. This reflection 
of increased risk has projected waist circumference (WC) as the leading compliment 
to BMI.1 
 Research was focused on individuals using outcome data from the National 
Health and Nutrition Examination Survey (NHANES) 1999-2004. Fourteen 
thousand, one hundred and five individuals were sampled of all ages, races, and 
gender. Z scores were calculated to control for age and gender. A fraction of 
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population mortality hazard from high values was calculated and uncertainty in this 
expression was approximated only to uncertainty in the numerator. 1 
 Krakauer, et al, followed up this initial research with a follow up to account 
for limitations identified in the NHANES sample. Waist to hip ratio (WHR) and waist 
to height ratio (WHtR) was not directly evaluated in initial sample. Also, 
anthropometrics measurements were only taken on one occasion so there was no 
way to assess ABSI over time. Follow up with participants was also relatively short 
at five years which further raises cause for concern of accuracy of ABSI over time. 
This body of work expanded samples to include information obtained from the 
Health and Lifestyle Survey (HALS). Researchers introduced HALS data to analysis 
methods, compared calculations to widely used anthropometric measures including 
WHR, and evaluated mortality as a function of change spaced 7 years apart. This 
research concluded that ABSI outperformed other measures of abdominal obesity as 
an indicator of mortality. Also, ABSI was a consistent predictor of mortality over at 
least 20 years of follow up. 2 
Other researchers took notice to this new and seemingly effective formula for 
obtaining risk of disease and applied it to populations in China to see if the 
calculation could predict new onset diabetes mellitus (DM) in the general 
population. Sen He, et al, applied the ABSI’s predictive power to the follow up data 
collected over 15 years from a general Chinese population. 711 participants from an 
urban community submitted data in 1992 and then again in 2007. Twenty four 
participants were diagnosed with DM in 1992 so their data was excluded. Complete 
data were obtained for 687 participants. Results supported the conclusion that ABSI 
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was an effective predictor of new onset diabetes mellitus. More research is needed 
involving other populations to confirm if ABSI is an effective predictor of new onset 
diabetes mellitus. 3 
Causes of insulin resistance include genetic or primary target cell defects, 
autoantibodies to insulin, and accelerated degradation of insulin. Mitochondrial 
dysfunction may play an important role in development of insulin resistance and 
complications. Obesity is the most common cause of insulin resistance due to the 
association with decreased number of receptors and post receptor failure to activate 
tyrosine kinase.⁴¯⁶ Physical inactivity also lowers the body’s sensitivity to insulin by 
similar mechanisms to obesity. This condition seems to be the cornerstone for the 
cause of other conditions involved with metabolic syndrome. Although, evidence 
suggests that there is an inverse relationship between IGF-1 and Metabolic 
Syndrome serum IGF-1 levels may be controlled to an extent with appropriate 
nutrition and activity.² 
 The next condition contributing to metabolic syndrome is hypertension. 
Blood pressure is the measurement of the force against the walls of arteries as the 
heart pumps blood through the body. Hypertension is defined as a consistent 
measurement of systolic over 130 or diastolic over 85 (NCEP-ATP III).⁴ Two types of 
hypertension have been identified and are referred to as primary or essential 
hypertension and secondary hypertension.  
 For most adults, primary hypertension has no identifiable cause of high 
blood pressure. This type tends to develop gradually over many years and is the 
result of several lifestyle factors including; diet (excess sodium intake, decreased 
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potassium intake), physical inactivity, smoking, stress, and obesity. Again, 
abdominal obesity being most correlated. There are no symptoms of hypertension 
so it may go years without any diagnosis.⁷ 
 Secondary hypertension is high blood pressure caused by an underlying 
condition. This condition tends to appear suddenly and cause a higher blood 
pressure than primary hypertension. Various conditions and medications can lead 
to secondary hypertension including; renal insufficiency or disease, adrenal gland 
tumors, certain congenital blood vessel defects, or medications such as birth control 
pills, cold remedies and decongestants, over the counter pain relievers, and 
prescription medications. Neither primary nor secondary hypertension has visible 
symptoms which is why hypertension is known as the “Silent Killer”.8 
 Another contributing factor in metabolic syndrome is atherogenic 
dyslipidemia which is defined as a triad of increased blood concentrations of small, 
dense low-density lipoprotein (LDL) particles, decreased high-density lipoprotein 
(HDL) particles, and increased triglycerides. HDL levels in men are considered low if 
under 40 mg/dL and under 50 mg/dL for women. Triglycerides are considered high 
in either gender if over 150 mg/dL. When combined with hypertension, the elevated 
LDL levels in the blood will react with cytokines released due to inflammation 
within blood vessels. Damage is usually found at a branch of the vessel caused by 
hypertension. LDL-cholesterol collects at the site of inflammation to form foam cells 
which, after time will cause hardening and thickening of the arterial walls 
compounding the problems associated with hypertension and increased cardiac 
output. Causes contributing to dyslipidemia may be primary (genetic) or secondary 
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and include; sedentary lifestyle, excess intake of saturated fatty acids, cholesterol, 
and trans-fatty acids, excess simple carbohydrate intake, alcohol abuse, chronic 
kidney disease, hypothyroidism, and medications such as corticosteroids and 
glucocorticosteroids.9 Much like hypertension, atherogenic dyslipidemia has little to 
no visible symptoms until sever elevations are present. The relationship between 
abdominal obesity and atherogenic dyslipidemia has been well established. 
Therefore, this research will focus on relationships of abdominal obesity with less 
information in current literature. 
 Those at risk for these conditions are individuals with poor eating habits and 
sedentary lifestyles. Usually individuals who are consuming an excess of a certain 
macronutrient such as saturated fat are also consuming an excess of energy as well. 
This is usually accompanied by a sedentary lifestyle and the two behavioral habits 
compound each other’s complications. Also, highly stressful lifestyles contribute to 
increasing risk of conditions. Furthermore, risks for conditions of metabolic 
syndrome as well as abdominal obesity increase with age. According to the Center 
for Disease Control, thirty four percent of individuals over the age of twenty meet 
the criteria for metabolic syndrome, men and women age forty to fifty nine are more 
than three times likely to meet criteria than those age twenty to thirty nine, men 
over age sixty are more than four times more likely to meet criteria than those age 
twenty to thirty nine, and women over age sixty are more than six times likely to 
meet criteria than those age twenty to thirty nine. 10 
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25(OH)D and IGF-1 
Further research supports the notion that vitamin D and IGF-1 are reduced 
with obesity. Since IGF-1 shares is able to bind with insulin receptors on cells, 
obesity leads to less insulin receptors to be present on cells for binding. A cross-
sectional cohort study conducted on primarily Caucasian individuals, age 45 years 
exhibited that lower serum concentrations of vitamin D and IGF-1 have been 
associated with adverse lipid profiles, hypertension, cardiovascular disease and 
disturbed glucose metabolism. 6,810 participants were contacted to answer 
questionnaires and submit blood sample to assess non fasting glucose and lipid 
profiles as well as serum 25(OH)D and IGF-1 levels. 78% of participants completed 
questionnaires and 81% submitted blood samples. Men resulted as having 
disturbed glucose metabolism, high blood pressure, and high triglycerides, although, 
low HDL-C and abdominal obesity was less prevalent in men. Abdominal obesity 
was most the most common indicator of Metabolic Syndrome present in 94.5% of 
men and 95.8% of women. All of these conditions will raise risk of metabolic 
syndrome.11-14 
 IGF-1 levels are strongly associated with changes with production and 
secretion of human growth hormone (HGH). Low secretion of HGH results in low 
levels of IGF-1 and acromegaly results in increased IGF-1. Age and sex also impact 
serum IGF-1 concentrations and at age 65 years, daily spontaneous secretion of HGH 
is reduced by 50-70% thus causing a decline in IGF-1 progressively. Normally, the 
male gender will exhibit a higher level of IGF-1 when compared to females of the 
same age.¹⁵ 
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 Subtle changes in IGF-1 have also been linked to changes in blood pressure 
(BP) and insulin sensitivity. IGF-1 levels in the upper normal range have produced 
results of reduced BP, vascular tone, and increased insulin sensitivity. 
Epidemiological studies have suggested IGF-1 levels in the lower normal range have 
been associated with increased risk of heart disease and stroke. A study of 174 
healthy individuals investigated IGF -1, IGFBP3, and intima-media thickness (IMT) 
of carotid artery and found that IGF-1 levels were the best predictors of total 
cholesterol and HDL-C.¹⁵ 
 Studies investigating relationships between IGF-1 and atherosclerosis have 
resulted in conflicting conclusions; some authors found a positive association 
between IGF-1 and IMT in both men and women, while others found an inverse 
association between IGF-1 and carotid IMT in healthy women.¹⁶ 
 Even though normal IGF-1 ranges have been established based on age and 
gender, they are quite contradictory. The normal reference range used in this study 
was established and used by the Mayo Clinic, however, other organizations as well 
as research studies have established various ranges as normal. The Mayo Clinic’s 
range was used because it reflected the lowest reference range based on age and 
gender. A study conducted on 1798 men and women age 25-85 years determined 
IGF-1 concentrations using chemiluminescent immunometric assay. Quantile 
regressions were then performed to calculate the 2.5 and 97.5 percentile. These 
reference ranges were substantially higher than those established by the Mayo 
Clinic.¹⁷ 
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Impact of Treatment on Vitamin D and IGF-1 Status 
Historically, clinicians’ first instinct to combating large waistlines and high 
levels of lipids and cholesterol in patients was to eliminate nearly all dietary fat in 
the diet. An example of one of these diets that is still in use by many physicians 
today is the Ornish Diet, developed by Dr. Dean Ornish. Dr. Ornish is a cardiologist 
with many accolades who also happens to be a vegetarian. His diet plan 
compliments his personal plant-based approach to reducing risk for coronary artery 
disease (CAD).  However, according to the research energy and protein restriction 
may actually cause a reduction in serum IGF-1 and IGFBP3.¹²  
Controversy exists in the effectiveness of following a plant-based diet to 
lower serum lipids. Comparing the Ornish diet to other diets high in animal fat and 
cholesterol resulted in unexpected outcomes. Subjects on a diet that did not limit 
cholesterol intake showed a greater decrease in systolic and diastolic blood 
pressures, a greater increase in insulin sensitivity, a greater decrease in 
triglycerides,  and an increase in HDL-C as well as a greater reduction in body mass 
and body fat when compared to subjects following the plant-based diet. The only 
category of secondary outcomes that the plant-based diet subjects showed a greater 
reduction was LDL-C.¹¹ This information was supplied by a study comparing dietary 
intake of whole eggs versus egg substitute among participants. In a randomized, 
single-blind, parallel design study, 37 participants were recruited to either consume 
3 whole eggs daily or the equivalent amount of yolk-free egg substitute over a 12 
week period. 20 participants were assigned to the whole egg group and 17 to the 
yolk-free egg substitute. Plasma lipids, apolipoproteins, oxidized LDL, cholesteryl 
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ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT) 
activities were assessed at baseline and week 12. Plasma triglycerides, apoC-III, 
apoE, oxLDL, VLDL particle diameter, large VDL, total IDL, small LDL, and medium 
LDL particles were reduced in all participants. HDL-C, large LDL, and large HDL 
particles also increased in all participants. However, there were greater increases in 
HDL-C and large HDL and reductions in VLDL and medium VLDL particles for those 
consuming whole egg compared to substitute. LDL-C is an important risk factor 
pertaining to CAD, however, the combination of all of the other categories have a far 
greater impact on risk for cardiovascular event. 
Another study focusing on nutritional approaches to reduce risk of CVD 
focused on dietary intake of low saturated fat but a higher intake of red meat 
presented results suggesting the intake of non-conventional foods for reducing 
lipids and cholesterol could actually have a great impact on reducing risk of CAD. 
Research based on beef in an optimal lean diet (BOLD diet) and the effects on lipids, 
lipoproteins, and apolipoproteins contained data that reflected that participants 
with the highest intake of red meat per day (~5.4 oz/day) had the most positive 
impact on triglycerides and LDL-C levels. Participants all presented with 
hypercholesterolemia (LDL-C >2.8 mmol/L) and were housed in a metabolic 
kitchen. There is no mention of a structured physical activity program that may have 
been followed. However, researchers were able to closely monitor daily behaviors 
and provide detailed, nutrient dense meals including lean cuts of red meat that still 
contains cholesterol. These lifestyle behaviors could have a positive impact on 
serum 25(OH)D and IGF-1.¹⁸ 
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 This is supported by research conducted exploring the inverse relationship 
between HDL-C or apolipoprotein A-I and cardiovascular events in women. Results 
showed a consistent inverse association with HDL-C and coronary events among 
participants with a range of LDL-C levels. An interesting portion of data within this 
study also reflected that those participants with the highest HDL-C levels also had 
the highest percentage of participants who exercised at least once or more per 
week. This infers that those who were most active also had the highest level of HDL-
C. This group also resulted with the lowest percentage of individuals developing 
diabetes, lowest percentage of smokers, lowest percentage of individuals developing 
hypertension, the lowest level of apolipoprotein B100, the lowest triglyceride level, 
and very nearly the lowest level of LDL-C.¹⁹ 
Impact of Physical Activity on Cardiovascular Disease 
The concept of physical activity is a major catalyst when it comes to reducing 
risk for CVD as well as reducing risk for obesity. Countless studies have reflected the 
beneficial impact of physical activity on the human body. One such study conducted 
suggested that time spent in vigorous activity is a significant indicator of total 
cholesterol and LDL-C with waist girth being a sole predictor of triglycerides and 
HDL-C. The study sought to explore the correlation of habitual exercisers, lean 
sedentary men, and abdominally obese sedentary men to risk of CVD. A cross-
sectional study recruited 113 non-smoking men age 30-45 years. CVD risk factors 
were assessed in these individuals and compared to exercisers, sedentary men, and 
in subgroups of lean men, lean sedentary men, and obese sedentary men. Blood 
pressure, physical activity (assessed with 7 day recall), physical fitness (assessed by 
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VO2 max), fasted lipoproteins, apolipoprotein B, triglycerides, glucose, and 
fibrinogen were assessed. Results showed exercisers were leaner and fitter than 
sedentary men and that leanness was associated with favorable HDL-C levels and 
triglycerides with or without exercise. However, exercise contributed to also having 
lower levels of total cholesterol, LDL-C, and apolipoprotein B. The subject group for 
this study was for individuals aged 30-45 years which reflects an age group that 
may still be active because they are still very ambulatory.²⁰ 
 Further research on physical activity indicates that muscle damage caused by 
exercise can up-regulate isoforms of IGF-1, primarily IGF-1Ea, IGF-1Eb, and IGF-1Ec. 
These isoforms are known as mechano growth factors (MGF) and are produced 
locally within the muscle. 10 healthy men were recruited, age 23-27 years, that were 
physically active and had not participated in any type of resistance training or 
regular exercise regime for at least 6 months prior to the study. Participants were 
instructed to not consume any medication, nutritional supplements, and maintain 
their habitual diet plans refraining from consuming alcohol through the duration of 
the study. Maximal eccentric exercise protocol of the knee extensor muscles in each 
leg was assessed in each participant. Biopsies and blood draws were taken in 
intervals prior, during, and post exercise. Serum levels of IGF-1 did not reflect any 
appreciable change, although MGF levels increased significantly. Increase in local 
growth factors could result in a major complimentary reaction within the body and 
increase insulin sensitivity.²¹ 
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Physical Activity in the Elderly 
The elderly may not be able to participate in vigorous activity for various 
reasons including disease or injury. Another study conducted included individuals 
from a more elderly population. 2,772 individuals were randomly enrolled and 
stratified by age and gender. Age ranged between 18-88 with the average age of 
men 45 +/- 12 yrs and average age of women 45 +/- 13 yrs. Physically active women 
showed a significantly lower level of serum cholesterol, LDL-C, and triglycerides. 
Men did not show a significant difference between physically active men compared 
to sedentary men, although the levels are more favorable in physically active men 
reinforcing the concept that the more physically active an individual is, the lower 
their risk of CVD.²² 
 Further research focused on physical activity primarily in the elderly 
population. Long-term follow up data was collected on a total of 89 coronary artery 
bypass graft (CABG) patients ranging from 55-88 years old. Subjects were divided 
into two groups based on daily physical activity being greater or less than thirty 
minutes. Surprisingly, only 26% of participants achieved the recommended thirty 
minutes per day of moderate intensity activity. These individuals who were most 
active again showed a more favorable profile of indicators of cardiovascular risk as 
well as lower body mass. Subjects were objectively monitored with double-labeled 
water, indirect calorimetry, pedometers, heart rate monitors, and accelerometry to 
assess true daily activity level. Higher physical activity was associated with higher 
apolipoprotein A-I levels and smaller apoB/apoAI ratios.²⁰ 
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Vitamin D and Skeletal Muscle 
Emerging research suggests that there may be a relationship with vitamin D 
and skeletal muscle mass, strength, and performance. No definitive mechanism has 
been identified to how vitamin D exerts these benefits, however, there are many 
rodent model as well as human model studies to support these suggestions. Vitamin 
D has traditionally been regarded as a regulator of bone metabolism and serum 
calcium and phosphate levels. Although, recent evidence suggests that the 
biologically active form of vitamin D, 1, 25-dihydroxyvitamin D (1,25(OH)2D) has a 
role in nuclear transcription as well as several components of cellular metabolism 
via the vitamin D receptor (VDR). Mechanism of action and characterization has not 
been well established for nonnuclear VDR, however, the binding of 1,25(OH)2D to 
nonnuclear VDR is proposed to result in rapid cellular effects via formation of a 
second messenger of intracellular proteins. Localized VDR have been identified in 
human skeletal muscle through the use of biopsies.²³¯³⁴ 
Human aging may decrease expression of VDR and a positive association has 
been found between 25(OH)D and VDR concentration in skeletal muscle. Recent 
findings reflected an increase in VDR mRNA in human myoblasts treated with 
1,25(OH)2D. Another study on 14 older, vitamin D deficient women discovered that 
intramyonuclear VDR concentration increased 30% with vitamin D3 
supplementation compared with placebo over a 4 month period.²³ 
1, 25(OH)2D is theorized to alter the activity of calcium pumps via a calcium 
binding protein located in the sarcoplasmic reticulum and sarcolemma which will 
impact muscle contraction by modulating cell calcium flux. Administration of 1, 
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25(OH)2D regulates the expression of genes involved in these cellular processes of 
calcium handling. Also, 1,25(OH)2D may increase calmodulin synthesis resulting in 
influence on muscle contraction.²³ʼ²⁶¯³⁴ 
Research focusing on individuals with insulin resistance revealed that 
decreased levels of serum 25(OH)D, 1,25(OH)2D, and elevated levels of serum 
parathyroid hormone can lead to an increase in intracellular calcium in adipocytes, 
which can stimulate lipogenesis further predisposing individuals to weight gain and 
increase their risk of developing type 2 diabetes. Furthermore, administering 
vitamin D to individuals with type 2 diabetes has been shown to decrease insulin 
resistance. However, similar administration of vitamin D in individuals with 
prediabetes has not been well established. 157 participants with prediabetes were 
evaluated in the study and results showed that serum 25(OH)D had a relatively 
strong inverse correlation with measures of insulin resistance and positive 
correlation with insulin sensitivity.³¹¯³⁴ 
Vitamin D has also been shown to play a role in muscle growth by its effect 
on anabolic signaling pathways. In a rat model study, rats consuming an alkali diet 
receiving vitamin D3 supplementation enhanced phosphorylated Akt protein kinase 
B (Akt) concentration which is an established component of the skeletal muscle 
anabolic cascade. Upregulation of Akt will stimulate myogenesis in cells potentially 
through a VDR mechanism.²³ 
Regulation of non-muscle tissue inflammation has also been related to 
vitamin D status through suppression of several serum proinflammatory cytokines. 
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This suggests that maintaining optimal levels of vitamin D may reduce risk of 
atherosclerosis.²³ 
The notion of inflammation increasing risk for CVD is further supported by 
research focusing on the sub-acute inflammation that accompanies obesity. Obesity 
has been shown to increase inflammation in immune as well as parenchymal cells 
within adipose tissue, liver, and vasculature. Within these tissues there is an 
abnormal production of cytokines and chemokines that may further attract and 
activate immune cells. Obese subjects also illicit increases in both amount and 
activation of peripheral mononuclear cells and exhibit an increase in serum levels of 
cytokines. Large scale studies contain evidence that markers of inflammation in 
aggregate predict incident type 2 diabetes. A particularly interesting inclusion in the 
study investigated reduction on inflammatory markers in patients who had 
undergone Roux-en-Y bypass procedures and while the procedure resulted in a 
marked reduction in adipose tissue macrophages and crown like structures, the 
degree of improvement in insulin sensitivity 3 months post-surgery did not 
correlate to adipose tissue macrophages.³⁴ 
Abdominal obesity has been shown to be a strong independent indicator of 
25(OH)D status in humans with obese individuals presenting with insufficient or 
deficient status. Although appropriate 25(OH)D status is still under debate in the 
medical community, the Institute of Medicine currently defines vitamin D deficiency 
as <50 nmol/L-1 or <20 ng/dL-1. 35 Two perspectives on why this occurs have come 
to the forefront of research, however, evidence is limited for both. The first 
perspective is that in vitro studies have reflected that the VDR and 1-α-hydroxylase 
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enzyme are present in adipose tissue. Researchers observed that 3T3-L1 pre-
adipocytes express the VDR and subsequently that by 10 days after differentiation, 
these adipocytes express receptors for vitamin D and parathyroid hormone (PTH). 
Rat models recently found the presence of the 1-α-hydroxylase enzyme in these 
3T3-L1 pre-adipocytes as well which is why adipose tissue is regarded as 
metabolically active and may be regulated and regulate vitamin D. 36-42 
The second perspective focuses on obese individuals having altered vitamin 
D and PTH physiology. Several studies on obese patients reflect low levels of 
circulating 25(OH)D and elevated levels of PTH. Much of the most recent 
information on this phenomenon, is derived from research on bariatric surgery 
patients. These patients report preoperatively with low circulating 25(OH)D (<80 
nmol/L on average). Other studies on these patients also indicated that BMI and 
body fat were inversely related to 25(OH)D. Despite the growing amount of 
evidence to support the low levels of circulating 25(OH)D in obese individuals, the 
relationship between obesity and the active form of vitamin D remains unclear due 
to the natural endocrine response to elevate PTH when low circulating 25(OH)D is 
present. This is where controversy lies. Some researchers have observed that the 
best indicator of vitamin D status in overweight and obese individuals is the 
substrate 25(OH)D while others have observed that the best indicator is the active 
form 1, 25(OH)2D itself. 36-42 This raises the question, does obesity cause poor 
vitamin D status or does poor vitamin D status cause obesity? Our research hopes to 
contribute valuable information to further answer these questions. 
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CHAPTER 3 
 
METHODOLOGY 
Subjects and Design 
 
Subjects: As part of a cross-sectional correlation study, participants were males (7) 
and females(19) (n=26), ages 25-65, who are students at UNLV and/or individuals 
who attend local health and wellness facilities as well as attendees of classes held by 
the UNLV Nutrition Center. Individuals were excluded if there were pregnant as this 
may cause unusual hormone status.  
Research Procedures: Participants reported to UNLV to review and sign informed 
consent, complete a food frequency and physical activity questionnaire, and submit 
a finger stick blood draw under sterile conditions as well as resting blood pressure 
and waist circumference. Blood Pressure was obtained using a sphygmomanometer 
and stethoscope taken on the right arm of each participant while in a seated 
position. Waist circumference was obtained at the umbilicus using a flexible tape 
measure.43 Questionnaires were administered prior to collecting blood pressure to 
allow blood pressure to reach a resting rate. This study was reviewed and approved 
by the UNLV Institutional Review for Biomedical Research. 
Framingham Food Frequency Questionnaires (FFQ) were used to establish if 
there were any unusual eating patterns as well as any supplementation taken by 
participants. Framingham scores are considered the most reliable when predicting 
risk of developing cardiovascular disease.44 The International Physical Activity 
Questionnaires (IPAQ) was used to assess if there were unusual levels of physical 
activity or unusual time spent indoors/outdoors. Both questionnaires have been 
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validated to produce repeatable results.44-45 If participants were to report unusual 
eating or physical activity behavior it could lead to obscure results. 
Participants were then escorted to BHS 119 laboratory where sterile 
instruments were used to obtain finger stick blood samples. The ring finger of the 
participant’s non-dominant hand was prepped using 70% isopropyl alcohol swabs. 
Terumo 1.5 mm width by 1.5 mm diameter were then used to penetrate the skin of 
the finger and initiate blood draw. 600 µL were collected in Multivette 600 capillary 
tubes. Once the target amount of blood was acquired, participants were given sterile 
gauze dressing to be applied to wound for no less than two minutes as well as a 
band aid to wear following the gauze protocol.  
Blood was then spun using a centrifuge for no less than five minutes to 
separate plasma. Plasma was then collected using a micro pipette with a sterile tip 
for each sample and stored in Eppendorf tubes in -70 degree freezer for later 
assessment. Remaining fluid was discarded following appropriate protocol in 
biohazard waste containers. 
 Plasma samples collected were used to obtain serum 25(OH)D and IGF-1 
levels using Immunodiagnostic System ELISA kits. 25-Hydroxyvitamin D 
enzymeimmunoassay (EIA), product code AC-57F1, and IGF-1 
immunoenzymometric assay (IEMA), product code AC-27F1 were used to determine 
serum levels of each respective substrate.  
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25(OH)D EIA Procedures: 25 µL of each calibrator and sample where combined with 
1mL of 25-D Biotin Solution and mixed with a vortex machine thoroughly for 10 
seconds. 200 µL of each diluted calibrator and sample where then placed in 
appropriate wells in duplicate on the Antibody Coated Plate. Plate was then covered 
with adhesive plate sealer (provided with kit) and left to incubate for 2 hours at 
room temperature. Following incubation period, all wells were then washed 3 times 
with 300 µL of Wash Solution. Following third wash, wells were then decanted by 
inverting sharply. 250 µL of wash was added to all wells and decanting process was 
repeated twice. 200 µL of Enzyme Conjugate was added to all wells using 
multichannel pipette. Wash and decant process was then repeated. 200 µL of TMB 
Substrate was added to all wells. Plate was covered again with adhesive plate sealer 
and set aside to incubate for 30 minutes. Following incubation, 100 µL of Stop 
Solution was added to all wells. Absorbance was then measured using microplate 
reader and results were calculated. 
Figure 1: 25-Hydroxyvitamin D ELISA Results 
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IGF-1 IEMA Procedures: 25 µL of each calibrator and sample were combined with 
100 µL of Releasing Reagent, vortexed for thoroughly, and set aside to incubate at 
room temperature for 10 minutes. 1.0 mL of Sample Diluent was added to each and 
vortexed thoroughly. 50 µL of each diluted calibrator and sample was then added in 
duplicate to appropriate wells of the Antibody Coated Plate. 200 µL of Enzyme 
Conjugate was added to all wells using a multichannel pipette. Plate was then set 
aside to incubate for 2 hours at room temperature. Following incubation, wells were 
washed 3 times with 300 µL of Wash Solution. Following third wash, wells were 
then decanted by inverting sharply. 250 µL of wash was added to all wells and 
decanting process was repeated twice. 200 µL of TMB Substrate was added to all 
wells using a multichannel pipette and set aside to incubate for 30 minutes. 
Following incubation, 100 µL of Stop Solution was added to all wells. Absorbance 
was then measured using microplate reader and results were calculated. 
Figure 2: IGF-1 ELISA Results 
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Metabolic Panel: Participants then reported to a local Quest Diagnostics at their 
convenience to obtain a fasting comprehensive metabolic panel. Data were collected 
and analyzed using a paired t-test. 
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CHAPTER 4 
 
FINDINGS 
Table 1: Participant Data 
 
Participant Gender Waist Cir 
25(OH)D 
nmol/L 
IGF-1 
µg/L 
1 F 29 163.9 109.5 
2 M 34.5 54.4 63.2 
3 M 34 104.6 47.1 
4 F 25.75 170.1 90.2 
6 F 26 133.9 53.7 
7 F 31.25 102.9 57.2 
10 F 33.5 297.5 41.5 
11 F 30.5 216.5 78.1 
12 F 28.5 239.5 69.1 
A F 29.5 97.8 53.7 
C F 29 115.7 50.9 
E M 31 150.8 66.8 
H M 36 147.1 48.3 
J F 26.5 144.1 75.6 
K F 28.5 140.2 79.4 
L M 30.5 301.3 59.3 
MEAN   30.25 161.26875 65.225 
STDEV   3.050956 69.93581551 17.94096 
          
Participant   Waist Cir 
25(OH)D 
nmol/L 
IGF-1 
µg/L 
5 M 48 268.9 40.6 
8 F 39 67.3 78 
9 F 38 158.9 68.6 
13 M 48 154.9 63.8 
B F 40.5 65.6 36.6 
D F 35.5 83.2 46.6 
F F 45 157.1 41.2 
G F 36.5 144.8 54.7 
I F 37 45 75.5 
M F 39 258 46.2 
MEAN   40.65 140.37 55.18 
STDEV   4.672912 77.8205921 15.25988 
 
 
 
 
Table 1 reflects data collected from each participant regarding gender, waist 
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circumference, 25(OH)D, and IGF-1 levels. Participants are separated according to 
waist circumference group with normal waist circumference in the upper portion 
and large waist circumference in the lower portion.  
Table 2: t-Test Assuming Equal Variances: Waist Circumference 
 
Table 2 reflects data collected regarding the waist circumference of participants of 
both genders resulted in a significant difference between the normal waist 
circumference group and the large waist circumference group (P = 0.000002). 
 
 
 
 
 
 
 
 
t-Test: Two-Sample Assuming Equal Variances Waist Circumference
Variable 1 Variable 2
Mean 30.25 40.65
Variance 9.308333 21.83611
Observations 16 10
Pooled Variance 14.00625
Hypothesized Mean Difference 0
df 24
t Stat -6.89359
P(T<=t) one-tail 1.98E-07
t Critical one-tail 1.710882
P(T<=t) two-tail 3.96E-07
t Critical two-tail 2.063899
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Relationship between IGF-1, and Waist Circumference 
Figure 3: Scatter Plot Correlation of IGF-1 to Waist Circumference 
 
Figure 3 reflects data collected regarding the correlation between waist 
circumference and IGF-1. Results found a significant correlation between waist 
circumference and IGF-1 (P=.006) 
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Table 3: Correlation of IGF-1 to Waist Circumference 
Correlations 
 
Waist_Circumfer
ence IGF1 
Waist_Circumference Pearson Correlation 1 -.525** 
Sig. (2-tailed)  .006 
N 26 26 
IGF1 Pearson Correlation -.525** 1 
Sig. (2-tailed) .006  
N 26 26 
 
Table 3 reflects data collected regarding the correlation between waist 
circumference and IGF-1. Results found a significant correlation between waist 
circumference and IGF-1 (P=.006) 
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Relationship between 25-Hydroxyvitamin D and Waist Circumference 
Figure 4:  Scatter Plot of 25(OH)D to Waist Circumference 
  
Figure 4 reflects data collected regarding the correlation between waist 
circumference and 25(OH)D. No significant difference was found (P = 0.649). 
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Table 4: Correlation of 25(OH)D to Waist Circumference 
Correlations 
 
Waist_Circumfer
ence VITD 
Waist_Circumference Pearson Correlation 1 -.094 
Sig. (2-tailed)  .649 
N 26 26 
VITD Pearson Correlation -.094 1 
Sig. (2-tailed) .649  
N 26 26 
 
Table 4 reflects data collected regarding the correlation between waist 
circumference and 25(OH)D. No significant difference was found (P = 0.649). 
Table 5: t-Test Assuming Equal Variances IGF-1 
t-Test: Two-Sample Assuming Equal Variances IGF-1 
 
   
  
Variable 
1 
Variable 
2 
Mean 65.225 55.18 
Variance 321.878 232.864 
Observations 16 10 
Pooled Variance 288.4978 
 Hypothesized Mean Difference 0 
 df 24 
 t Stat 1.467074 
 P(T<=t) one-tail 0.077669 
 t Critical one-tail 1.710882 
 P(T<=t) two-tail 0.155339 
 t Critical two-tail 2.063899   
 
Table 5 reflects data in regards to large waist and normal waist circumference 
groups and their level of IGF-1. No significant difference was found between the 
groups (P=0.08). 
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Table 6: t-Test Assuming Equal Variances 25(OH)D 
t-Test: Two-Sample Assuming Equal Variances 25(OH)D 
   
  
Variable 
1 Variable 2 
Mean 161.2688 140.37 
Variance 4891.018 6056.044556 
Observations 16 10 
Pooled Variance 5327.903 
 Hypothesized Mean Difference 0 
 df 24 
 t Stat 0.710257 
 P(T<=t) one-tail 0.242195 
 t Critical one-tail 1.710882 
 P(T<=t) two-tail 0.48439 
 t Critical two-tail 2.063899   
 
Table 6 reflects data in regards to large waist and normal waist circumference 
groups and their level of 25(OH)D. No significant difference was found between the 
groups (P=0.24). 
 Groups were also separated according to gender and the same statistical 
analysis were evaluated. Within our data set, gender did not seem to influence 
results, however, our sample group contained primarily female participants. Data 
collected reflects a definitive separation of participant groups according to waist 
circumference to be used to assess other relationships within the data. 
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CHAPTER 5 
 
DICUSSION AND IMPLICATIONS  
Discussion 
 
The purpose of this study was to assess if there was a relationship between 
25(OH)D, IGF-1, and waist circumference. A significant relationship was found 
between IGF-1 and waist circumference, however, 25(OH)D was not found to have a 
significant relationship to waist circumference. No significant difference was found 
in both IGF-1 and 25(OH)D between large waist and normal waist circumference 
groups.  It is worth mentioning that only 5 of the 26 participants presented with 
sufficient IGF-1 (according to normal reference range17). Also, only 1 participant 
presented with 25(OH)D levels borderline insufficient. 
Table 7: Normal Reference Range IGF-1 
21-25 years 83-344   
26-30 years 75-275   
31-35 years 71-241   
36-40 years 69-226   
41-45 years 64-210   
46-50 years 59-201   
51-55 years 56-201   
56-60 years 51-194   
61-65 years 47-191   
 
Males      Females 
Table 7 indicates normal reference ranges of free IGF-1 according to information 
derived from Mayo Clinic Laboratories.17 
 
21-25 years 84-323   
26-30 years 77-271   
31-35 years 73-244   
36-40 years 68-225   
41-45 years 62-205   
46-50 years 56-194   
51-55 years 53-191   
56-60 years 45-173   
61-65 years 41-168   
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This research project was unique from other similar research projects in the 
ability of investigators to interact personally and obtain detailed information 
regarding nutritional intake and physical activity. According to data collected in 
food frequency and physical activity questionnaires, all participants ate a relatively 
well-balanced diet that included decent sources of vitamin D. All participants also 
maintained a relatively active lifestyle. Active lifestyles could enhance the 
participant’s insulin sensitivity as well as up-regulate IGF-1 production allowing for 
their IGF-1 to operate more efficiently. However, our results indicated that the 
majority of participants still exhibited low levels of IGF-1.  
Another aspect to consider is that data was collected in the later part of 
spring and early summer in a desert climate. Participants could easily obtain 
additional vitamin D from being outside. Within our data set, gender did not seem to 
influence results, however, our sample group contained primarily female 
participants. Future research including a larger representation of male population 
would be beneficial to identify possible relationships between 25(OH)D, and waist 
circumference. 
Conclusion 
Risks associated with large waist circumference, low IGF-1, and low 25(OH)D 
can lead to metabolic syndrome and if left untreated can be fatal. These risks also 
include a variety of complications such as; higher risk of cardiovascular event, sleep 
apnea, aortic stiffness, hypertension, joint pain, respiratory distress, and all of the 
complications involved will compound each other furthering progression of the 
syndrome. All of the conditions of metabolic syndrome can be controlled through 
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diet, exercise, and lifestyle changes, however, few patients are able to make or 
adhere to the necessary changes to reduce the risk involved.  
Both ELISA kits displayed acceptable accuracy. Despite all participants 
displaying sufficient amounts of serum 25(OH)D, only 5 participants displayed 
sufficient serum IGF-1. Insufficient serum IGF-1 may suggest possible human 
growth hormone (HGH) deficiency, however, more information regarding 
participants’ IGF-1 binding proteins would be required to fully assess this condition. 
Theoretically, evidence reviewed in this project suggests that insufficient serum 
IGF-1 levels can be treated pharmaceutically as well as through lifestyle 
modification.  
Future Research 
Future research including accurate information regarding all binding 
proteins of IGF-1 as well as a more detailed account of daily behavior by a larger 
sample of participants would very useful in assessing relationships between 
25(OH)D, IGF-1, and waist circumference. Large waist circumference could be 
related to many risk factors for disease, however, maintaining a relatively active 
lifestyle may slightly reduce the risk for individuals who have large waist 
circumferences. Obtaining waist circumference as well as activity level is relatively 
convenient in medical treatment settings and could provide clinicians with more 
valuable information regarding patient’s level of risk for disease. This information 
could provide researchers and clinicians with practical information that could be 
used to formulate patient care plans that could greatly reduce their risk for 
cardiovascular event. 
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APPENDIX I: INFORMED CONCENT 
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APPENDIX II: FOOD FREQUENCY QUESTIONNAIRE  
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APPENDIX III: PHYSICAL ACTIVITY QUESTIONNAIRE 
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APPENDIX IV: DESCRIPTIVE STATISTICS FOR ALL SUBJECTS 
 
 
 
 
 
 
  
 
53 
 
APPENDIX V: IGF-1 ELISA RESULTS 
 
 
 
OD 1 OD 2 MEAN LOGMEAN CONC 
0.615 0.61 0.6125 2.039568 109.5 
0.415 0.39 0.4025 1.800796 63.2 
0.295 0.286 0.2905 1.673451 47.1 
0.497 0.58 0.5385 1.955429 90.2 
0.234 0.233 0.2335 1.608641 40.6 
0.335 0.345 0.34 1.729733 53.7 
0.367 0.362 0.3645 1.75759 57.2 
0.476 0.49 0.483 1.892325 78 
0.423 0.444 0.4335 1.836043 68.6 
0.237 0.246 0.2415 1.617737 41.5 
0.482 0.485 0.4835 1.892894 78.1 
0.445 0.428 0.4365 1.839454 69.1 
0.444 0.368 0.406 1.804775 63.8 
0.329 0.351 0.34 1.729733 53.7 
0.19 0.197 0.1935 1.563161 36.6 
0.317 0.324 0.3205 1.707561 50.9 
0.289 0.283 0.286 1.668334 46.6 
0.458 0.389 0.4235 1.824673 66.8 
0.236 0.242 0.239 1.614895 41.2 
0.36 0.334 0.347 1.737692 54.7 
0.279 0.32 0.2995 1.683684 48.3 
0.5 0.441 0.4705 1.878113 75.5 
0.489 0.455 0.472 1.879818 75.6 
0.493 0.486 0.4895 1.899716 79.4 
0.384 0.372 0.378 1.772939 59.3 
0.274 0.291 0.2825 1.664355 46.2 
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APPENDIX VI: IGF-1 ELISA VALIDATION 
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APPENDIX VII: 25(OH)D ELISA RESULTS 
 
 
 
OD 1 OD 2 MEAN LOGMEAN CONC 
1.431 0.896 1.1635 2.214529 163.9 
1.763 1.688 1.7255 1.735905 54.4 
1.784 1.001 1.3925 2.019503 104.6 
1.422 0.867 1.1445 2.23071 170.1 
0.939 0.883 0.911 2.429569 268.9 
1.738 0.795 1.2665 2.12681 133.9 
1.874 0.928 1.401 2.012264 102.9 
1.726 1.508 1.617 1.828309 67.3 
1.201 1.157 1.179 2.201329 158.9 
0.903 0.816 0.8595 2.473429 297.5 
1.047 0.996 1.0215 2.335462 216.5 
1.171 0.769 0.97 2.379322 239.5 
1.398 0.986 1.192 2.190257 154.9 
2.005 0.848 1.4265 1.990547 97.8 
1.631 1.63 1.6305 1.816811 65.6 
1.726 0.956 1.341 2.063362 115.7 
1.201 1.817 1.509 1.920286 83.2 
0.903 1.509 1.206 2.178334 150.8 
1.047 1.323 1.185 2.196219 157.1 
1.171 1.282 1.2265 2.160875 144.8 
1.398 1.039 1.2185 2.167689 147.1 
2.005 1.64 1.8225 1.653296 45 
1.631 0.827 1.229 2.158746 144.1 
1.088 1.398 1.243 2.146823 140.2 
0.923 0.783 0.853 2.478964 301.3 
0.914 0.95 0.932 2.411685 258 
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APPENDIX VIII: 25(OH)D ELISA VALIDATION 
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APPENDIX IX: t-TEST ASSUMING EQUAL VARIANCES: WAIST 
CIRCUMFERENCE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-Test: Two-Sample Assuming Equal Variances Waist Circumference
Variable 1 Variable 2
Mean 30.25 40.65
Variance 9.308333 21.83611
Observations 16 10
Pooled Variance 14.00625
Hypothesized Mean Difference 0
df 24
t Stat -6.89359
P(T<=t) one-tail 1.98E-07
t Critical one-tail 1.710882
P(T<=t) two-tail 3.96E-07
t Critical two-tail 2.063899
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APPENDIX X: t-TEST ASSUMING EQUAL VARIANCES: IGF-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-Test: Two-Sample Assuming Equal Variances IGF-1
Variable 1 Variable 2
Mean 65.225 55.18
Variance 321.878 232.864
Observations 16 10
Pooled Variance 288.4978
Hypothesized Mean Difference 0
df 24
t Stat 1.467074
P(T<=t) one-tail 0.077669
t Critical one-tail 1.710882
P(T<=t) two-tail 0.155339
t Critical two-tail 2.063899
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APPENDIX XI: t-TEST ASSUMING EQUAL VARIANCES: 25(OH)D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t-Test: Two-Sample Assuming Equal Variances Vitamin D
Variable 1 Variable 2
Mean 161.2688 140.37
Variance 4891.018 6056.044556
Observations 16 10
Pooled Variance5327.903
Hypothesized Mean Difference0
df 24
t Stat 0.710257
P(T<=t) one-tail0.242195
t Critical one-tail1.710882
P(T<=t) two-tail0.48439
t Critical two-tail2.063899
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